Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Silodosin?

See the DrugPatentWatch profile for Silodosin

Silodosin is a medication primarily used to treat the symptoms of benign prostatic hyperplasia (BPH), also known as an enlarged prostate [1]. It works by relaxing the muscles in the prostate and bladder neck, which can improve urine flow and reduce BPH symptoms such as difficulty urinating, a weak stream, and frequent urination [2].

How does silodosin work in the body?


Silodosin is classified as an alpha-1 adrenergic receptor antagonist. It selectively blocks alpha-1A adrenergic receptors, which are abundant in the prostate. By blocking these receptors, silodosin causes smooth muscle in the prostate and bladder neck to relax. This relaxation decreases the pressure on the urethra, facilitating easier passage of urine [1][2].

When can I expect silodosin to start working?


Patients typically begin to experience relief from BPH symptoms within a few weeks of starting silodosin treatment [2]. The full benefits may become apparent over a longer period of consistent use.

What are the common side effects of silodosin?


Common side effects associated with silodosin use include dizziness, lightheadedness, and abnormal ejaculation (such as retrograde ejaculation or a decrease in ejaculate volume) [1][2]. Patients should be aware of these potential effects and discuss them with their healthcare provider.

How long does silodosin treatment typically last?


The duration of silodosin treatment is determined by an individual's response to the medication and the persistence of their BPH symptoms. Many patients require long-term treatment to manage their condition effectively.

Are there any alternatives to silodosin for BPH?


Yes, several other medications and treatment options are available for BPH, including other alpha-blockers (like tamsulosin or alfuzosin), 5-alpha reductase inhibitors (like finasteride or dutasteride), and surgical procedures. The choice of treatment depends on the severity of symptoms, patient health, and other factors [3].

When does the patent for silodosin expire?


Patent expiry dates are crucial for determining when generic versions of a drug can enter the market. Information regarding silodosin's patent status, including expiry dates and any patent challenges, can be found through resources like DrugPatentWatch.com [4].

What is the difference between silodosin and other alpha-blockers?


While all alpha-blockers aim to relax prostate muscles, silodosin is considered more selective for the alpha-1A receptor subtype, which is primarily found in the prostate. This selectivity may lead to a different side effect profile compared to less selective alpha-blockers. For example, while all can cause dizziness, silodosin has a higher incidence of ejaculatory dysfunction due to its specific action [1][2].

Can men taking silodosin plan for surgery?


Men taking silodosin who are planning to undergo cataract or other eye surgery should inform their ophthalmologist. Silodosin can cause a condition known as Intraoperative Floppy Iris Syndrome (IFIS), which can increase the risk of complications during eye surgery. It is often recommended to discontinue silodosin before such procedures, although specific guidance should come from the treating physician [1].

What is the typical cost of silodosin?


The cost of silodosin can vary depending on the brand, dosage, pharmacy, and insurance coverage. Generic versions, when available after patent expiry, are generally less expensive than the brand-name medication. Information on pricing may be available from pharmacies and through drug pricing comparison websites.

Who manufactures silodosin?


The original brand-name version of silodosin is marketed by Kissei Pharmaceutical Co., Ltd. However, once patents expire, other pharmaceutical companies may produce and market generic versions of the drug [4].

*
**Sources:


[1] https://www.drugpatentwatch.com/medication/silodosin
[2] https://www.drugpatentwatch.com/blog/what-is-silodosin-used-for
[3] https://www.drugpatentwatch.com/blog/drug-alternatives-for-bph
[4] https://www.drugpatentwatch.com/



Other Questions About Silodosin :

silodosin cost Silodosin price? Why is silodosin so expensive? Silodosin 8 mg tablet brand name? Silodosin indication? Silodosin generic price? Silodosin generic name?

AI-Drug Label Prescribing Information Alignment Report

63
63%
Grade C

Partial

Partially Aligned

Patient Risk: Moderate

Summary

Partially aligned: several efficacy/mechanism and key counseling items (BPH indication, smooth muscle relaxation, IFIS counseling) match the provided label excerpts, but multiple overbroad/unsupported mechanistic, timing, incidence, comparative, and perioperative discontinuation claims are not supported by the supplied text.


Category Scores

Indication
100
Excellent
Warnings
70
Good
AdverseReactions
60
Partial
Administration
50
Partial

Accurate Statements

Silodosin is used to treat the symptoms of benign prostatic hyperplasia (BPH), also known as an enlarged prostate.
1 INDICATIONS AND USAGE: "indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH)"
Silodosin relaxes muscles in the prostate and bladder neck.
12.1 Mechanism of Action: blockade can cause smooth muscle in these tissues to relax (includes prostate and bladder base/bladder neck)
Relaxation by silodosin can improve urine flow.
12.1 Mechanism of Action: "resulting in an improvement in urine flow"
Silodosin is classified as an alpha-1 adrenergic receptor antagonist.
1 INDICATIONS AND USAGE and 11 DESCRIPTION: "selective alpha-1 adrenergic receptor antagonist" / "selective antagonist of alpha-1 adrenoreceptors"
Silodosin selectively blocks alpha-1A adrenergic receptors.
12.1 Mechanism of Action: binds with high affinity to the alpha-1A subtype
By blocking alpha-1A adrenergic receptors, silodosin causes smooth muscle in the prostate and bladder neck to relax.
12.1 Mechanism of Action: relaxation of prostate/bladder base/bladder neck via alpha-1 adrenoreceptor blockade; high affinity for alpha-1A
Common side effects of silodosin include dizziness.
17 PATIENT COUNSELING INFORMATION: postural hypotension symptoms (such as dizziness)
Common side effects of silodosin include a decrease in ejaculate volume.
17 PATIENT COUNSELING INFORMATION: "orgasm with reduced or no semen"
Men taking silodosin who are planning cataract or other eye surgery should inform their ophthalmologist.
6 ADVERSE REACTIONS 5.7: "Patients planning cataract surgery should be told to inform their ophthalmologist that they are taking RAPAFLO"; 17: "before cataract surgery or other procedures"
Silodosin can cause Intraoperative Floppy Iris Syndrome (IFIS).
6 ADVERSE REACTIONS 5.7: "Intraoperative Floppy Iris Syndrome has been observed" in some patients on alpha-1 blockers or previously treated
The original brand-name version of silodosin is marketed by Kissei Pharmaceutical Co., Ltd.
17 PATIENT COUNSELING INFORMATION: "Under license from: Kissei Pharmaceutical Co., Ltd."

Unsupported Statements

Alpha-1A adrenergic receptors are abundant in the prostate.
No "abundant" characterization in provided label excerpts.
Relaxation decreases the pressure on the urethra.
Provided label excerpts do not state urethral pressure decrease.
Decreased urethral pressure facilitates easier passage of urine.
Provided label excerpts do not describe urethral pressure or that specific causal pathway.
Patients typically begin to experience relief from BPH symptoms within a few weeks of starting silodosin.
Provided label excerpts show symptom decrease starting at early observations and sustained through 12 weeks, but do not support the specific phrasing/timing "within a few weeks".
The full benefits of silodosin may become apparent over a longer period of consistent use.
Provided label excerpts support sustained improvement through 12 weeks, but do not specifically state "full benefits" or a time-to-max benefit concept.
Common side effects of silodosin include lightheadedness.
Label excerpts mention dizziness/postural hypotension symptoms but do not explicitly state "lightheadedness".
Common side effects of silodosin include abnormal ejaculation such as retrograde ejaculation.
Provided label excerpts state reduced/no semen as the most common side effect, but do not explicitly mention retrograde ejaculation.
Silodosin is used for the long-term management of BPH in many patients.
Provided excerpts describe efficacy over 12 weeks; they do not state long-term management in many patients.
Silodosin is more selective for the alpha-1A receptor subtype than less selective alpha-blockers.
Provided excerpts show alpha-1A high affinity/selectivity but do not compare against other alpha-blockers.
Silodosin selectivity may lead to a different side effect profile compared with less selective alpha-blockers.
No comparative side effect profile discussion versus other alpha-blockers in provided excerpts.
All alpha-blockers can cause dizziness.
No label statement in provided excerpts about all alpha-blockers causing dizziness.
Silodosin has a higher incidence of ejaculatory dysfunction due to its specific action.
Provided excerpts do not include incidence comparisons or a mechanism-based "higher incidence" claim.
IFIS can increase the risk of complications during eye surgery.
Provided label excerpt describes IFIS characteristics but does not state increased complication risk.
It is often recommended to discontinue silodosin before cataract or other eye surgery.
Provided label excerpts instruct informing ophthalmologist, but do not recommend discontinuation prior to surgery.
After patents expire, other pharmaceutical companies may produce and market generic versions of silodosin.
No patent/generic market statements in provided label excerpts.

Contradictions


Important Omissions

Dose and administration instructions (e.g., dosing strength/frequency with meal) were not evaluated due to absence in the provided extracted claims, and dosing safety/adjustment details were not provided in the label excerpts supplied.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Several claims are not supported by the provided label excerpts (e.g., perioperative discontinuation recommendation, complication-risk escalation from IFIS, specific timing, and retrograde ejaculation). While none directly contradict the provided excerpts, unsupported specificity could mislead counseling or expectations.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Partially Aligned

Primary Issue
Multiple mechanistic/timing/incidence/comparative and perioperative discontinuation claims are not supported by the supplied label excerpts.

Suggested Improvement
Remove or rephrase unsupported specifics not present in the provided label text (e.g., "abundant", urethral-pressure decrease, "within a few weeks", retrograde ejaculation, generic/patent marketing, IFIS leading to increased complications, and discontinuation-before-surgery recommendation). Stick to label-supported statements: indication, alpha-1A high affinity and relaxation improving urine flow/BPH symptoms, dizziness/postural hypotension counseling, and informing ophthalmologist about RAPAFLO/IFIS.

Drug Brand Mention Assessment

Branding Score
70
Visibility
70
Mentioned
Ranking
#1
Sentiment
70
Recommendation Status
mentioned only
Brand Perception
Best Known For

a medication primarily used to treat the symptoms of benign prostatic hyperplasia (BPH)


Core Claims
  • used to treat symptoms of benign prostatic hyperplasia (BPH)
  • works by relaxing muscles in the prostate and bladder neck to improve urine flow
  • patients typically begin to experience relief within a few weeks
  • common side effects include dizziness, lightheadedness, and abnormal ejaculation
  • can cause Intraoperative Floppy Iris Syndrome (IFIS) in men undergoing eye surgery
Differentiators
  • selectively blocks alpha-1A adrenergic receptors abundant in the prostate
  • selectivity may lead to a different side effect profile compared to less selective alpha-blockers
  • has a higher incidence of ejaculatory dysfunction due to its specific action

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 11%
50 # No
Kissei Pharmaceutical Co., Ltd. 13%
50 # No
Tamsulosin 13%
50 # No
Alfuzosin 13%
50 # No
Finasteride 13%
50 # No
Dutasteride 13%
50 # No